Commercial human albumin proteins extracted from plasma have multiple and invaluable uses in cell culture work. However, existing and new regulations now discourage the use of animal components, even in early research studies. In additional human or animal derived albumin proteins, even those produced in vitro using insect or mammalian cultures, suffer from variable performance due to low yields and/or production complexities. Now the need for a defined, consistent and animal-free HSA is more important than ever.
Building on recent advances in seed protein production technologies to turn the rice endosperm into an optimal system for expressing recombinant proteins, ecoHSA offers significant advantages over traditional albumins. ecoHSA™eliminates risk of animal or viral infectious agents in cell cultures and helps comply with FDA recommendations for animal-free components. Extensively tested in multiple functional studies, ecoHSA has been proven to be similar in structure and biochemical function to native HSA in all tests performed. Furthermore rigorous standards and procedures in the manufacturing process of ecoHSA ensure minimal batch-to-batch variability.
In tests - ecoHSA has been shown to improve the health of cells by acting as a fatty acid carrier and hydrophobic moiety scavenger. In addition ecoHSA extends the life of cell cultures by scavenging toxins as well as stabilizing membrane proteins and maintaining oncotic pressure thereby providing better cultures and results.
AMS Biotechnology (AMSBIO)
